BRIEF-Seamless Therapeutics Announces Global Research Collaboration With Lilly To Develop Programmable Recombinase-Based Therapeutics For Hearing Loss

Reuters
Jan 28
BRIEF-Seamless <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Global Research Collaboration With Lilly To Develop Programmable Recombinase-Based Therapeutics For Hearing Loss

Jan 28 (Reuters) - Eli Lilly and Co LLY.N:

  • SEAMLESS THERAPEUTICS: ANNOUNCES GLOBAL RESEARCH COLLABORATION WITH LILLY TO DEVELOP PROGRAMMABLE RECOMBINASE-BASED THERAPEUTICS FOR HEARING LOSS

  • SEAMLESS: ELIGIBLE FOR OVER $1.12 BILLION, INCLUDING POTENTIAL DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS AS PART OF COLLABORATION

Source text: ID:nGNX9ff76P

Further company coverage: LLY.N

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10